作者
Robert J. Mayer,Eric Van Cutsem,Alfredo Falcone,Takayuki Yoshino,Rocio García‐Carbonero,Nobuyuki Mizunuma,Kentaro Yamazaki,Yasuhiro Shimada,Josep Tabernero,Yoshito Komatsu,Alberto Sobrero,Éveline Boucher,Marc Peeters,Ben Tran,Heinz‐Josef Lenz,Alberto Zaniboni,Howard S. Hochster,James M. Cleary,Hans Prenen,Fabio Benedetti,Hirokazu Mizuguchi,Lukas Makris,Masanobu Ito,Atsushi Ohtsu
摘要
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.